OrganiGram Holdings
Market Cap
CA$533.9m
Last Updated
2021/01/16 23:12 UTC
Data Sources
Company Financials +
Executive Summary
Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with high growth potential.
Similar Companies
Share Price & News
How has OrganiGram Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OGI is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: OGI's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
Market Performance
7 Day Return
7.0%
OGI
13.7%
CA Pharmaceuticals
-0.5%
CA Market
1 Year Return
-46.0%
OGI
47.2%
CA Pharmaceuticals
1.7%
CA Market
Return vs Industry: OGI underperformed the Canadian Pharmaceuticals industry which returned 47.2% over the past year.
Return vs Market: OGI underperformed the Canadian Market which returned 1.7% over the past year.
Shareholder returns
| OGI | Industry | Market | |
|---|---|---|---|
| 7 Day | 7.0% | 13.7% | -0.5% |
| 30 Day | 26.4% | 30.2% | 3.4% |
| 90 Day | 48.4% | 81.5% | 12.3% |
| 1 Year | -46.0%-46.0% | 47.2%47.2% | 5.3%1.7% |
| 3 Year | -52.5%-52.5% | -50.4%-51.1% | 13.0%2.3% |
| 5 Year | 187.5%187.5% | 414.4%410.9% | 66.2%40.7% |
Long-Term Price Volatility Vs. Market
How volatile is OrganiGram Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
Analysts Are More Bearish On OrganiGram Holdings Inc. (TSE:OGI) Than They Used To Be1 month ago | Simply Wall St
OrganiGram Holdings Inc. (TSE:OGI) Analysts Are More Bearish Than They Used To Be2 months ago | Simply Wall St
Does OrganiGram Holdings (TSE:OGI) Have A Healthy Balance Sheet?Valuation
Is OrganiGram Holdings undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OGI (CA$2.3) is trading below our estimate of fair value (CA$9.06)
Significantly Below Fair Value: OGI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OGI is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: OGI is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OGI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OGI is good value based on its PB Ratio (1.7x) compared to the CA Pharmaceuticals industry average (2.7x).
Next Steps
Future Growth
How is OrganiGram Holdings forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
62.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OGI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).
Earnings vs Market: OGI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: OGI's is expected to become profitable in the next 3 years.
Revenue vs Market: OGI's revenue (27.1% per year) is forecast to grow faster than the Canadian market (7.9% per year).
High Growth Revenue: OGI's revenue (27.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OGI's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has OrganiGram Holdings performed over the past 5 years?
-60.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OGI is currently unprofitable.
Growing Profit Margin: OGI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OGI is unprofitable, and losses have increased over the past 5 years at a rate of 60.6% per year.
Accelerating Growth: Unable to compare OGI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OGI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-61.1%).
Return on Equity
High ROE: OGI has a negative Return on Equity (-53.23%), as it is currently unprofitable.
Next Steps
Financial Health
How is OrganiGram Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: OGI's short term assets (CA$208.4M) exceed its short term liabilities (CA$78.3M).
Long Term Liabilities: OGI's short term assets (CA$208.4M) exceed its long term liabilities (CA$76.5M).
Debt to Equity History and Analysis
Debt Level: OGI's debt to equity ratio (36.2%) is considered satisfactory.
Reducing Debt: OGI's debt to equity ratio has reduced from 68.6% to 36.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OGI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if OGI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is OrganiGram Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OGI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OGI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OGI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OGI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OGI's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.5yrs
Average management tenure
CEO
Greg Engel (55 yo)
3.83yrs
Tenure
CA$1,074,643
Compensation
Mr. Gregory Engel, also known as Greg, has been Director of Canadian Chamber Of Commerce since October 2020. Mr. Engel has been Chief Executive Officer of OrganiGram Holdings Inc. since March 13, 2017. Mr....
CEO Compensation Analysis
Compensation vs Market: Greg's total compensation ($USD843.82K) is about average for companies of similar size in the Canadian market ($USD785.01K).
Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.83yrs | CA$1.07m | 0.032% CA$ 172.5k | |
| Chief Financial Officer | no data | CA$469.00k | 0.0041% CA$ 21.8k | |
| Senior Vice President of Sales & Commercial Operations | 3.25yrs | CA$563.50k | no data | |
| Chief Strategy Officer | 0.83yr | CA$852.71k | 0.020% CA$ 105.7k | |
| Senior Vice President of Operations | no data | no data | 0.0096% CA$ 51.3k | |
| Vice President of Investor Relations | 2yrs | no data | no data | |
| Senior VP of Strategic & Legal Affairs and Company Secretary | 1.75yrs | no data | no data | |
| Chief of Staff | no data | no data | no data | |
| Vice President of International Business Development | 3.25yrs | CA$222.73k | no data | |
| Director of Finance | 3.08yrs | CA$143.13k | no data |
2.5yrs
Average Tenure
50yo
Average Age
Experienced Management: OGI's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.83yrs | CA$1.07m | 0.032% CA$ 172.5k | |
| Chief Financial Officer | no data | CA$469.00k | 0.0041% CA$ 21.8k | |
| Director | no data | no data | no data | |
| Independent Chairman & Lead Director | 2.83yrs | CA$502.60k | 0.069% CA$ 368.0k | |
| Independent Director | 0.92yr | no data | 0.0044% CA$ 23.7k | |
| Independent Director | 2.08yrs | CA$283.45k | 0.0026% CA$ 14.1k | |
| Independent Director | 0.92yr | no data | no data | |
| Independent Director | 0.92yr | no data | 0.0019% CA$ 10.4k | |
| Independent Director | 2.08yrs | CA$280.71k | 0.0030% CA$ 16.1k |
2.1yrs
Average Tenure
59yo
Average Age
Experienced Board: OGI's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 41.9%.
Top Shareholders
Company Information
OrganiGram Holdings Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: OrganiGram Holdings Inc.
- Ticker: OGI
- Exchange: TSX
- Founded: 2013
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$533.851m
- Shares outstanding: 232.11m
- Website: https://www.organigram.ca
Number of Employees
Location
- OrganiGram Holdings Inc.
- 35 English Drive
- Moncton
- New Brunswick
- E1E 3X3
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| OGI | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Aug 2014 |
| OGI | NasdaqGS (Nasdaq Global Select) | Yes | Common Shares | US | USD | Aug 2014 |
| 0OG | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Aug 2014 |
| 0VB6 | LSE (London Stock Exchange) | Yes | Common Shares | GB | CAD | Aug 2014 |
Biography
Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers cannabis flowers, extracts, edibles and oils, beverages, and other cannabi...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/16 23:12 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/11/30 |
| Annual Earnings | 2020/08/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.